Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Apo Pravastatin
2. Apo-pravastatin
3. Bristacol
4. Cs 514
5. Cs-514
6. Cs514
7. Elisor
8. Eptastatin
9. Lin Pravastatin
10. Lin-pravastatin
11. Lipemol
12. Liplat
13. Lipostat
14. Mevalotin
15. Nu Pravastatin
16. Nu-pravastatin
17. Prareduct
18. Pravachol
19. Pravacol
20. Pravasin
21. Pravastatin
22. Pravastatin Monosodium Salt, (6 Beta)-isomer
23. Pravastatin Sodium Salt
24. Pravastatin Tert Octylamine Salt
25. Pravastatin Tert-octylamine Salt
26. Pravastatin, (6 Beta)-isomer
27. Rms 431
28. Rms-431
29. Rms431
30. Selektine
31. Sodium Salt, Pravastatin
32. Sq 31,000
33. Sq 31000
34. Sq-31,000
35. Sq-31000
36. Sq31,000
37. Sq31000
38. Vasten
1. 81131-70-6
2. Pravachol
3. Mevalotin
4. Selektine
5. Elisor
6. Pravaselect
7. Lipostat
8. Eptastatin Sodium
9. Cs-514
10. Pravastatin Sodium Salt
11. Pravastatin (sodium)
12. Dehypotin Protect
13. Sq-31000
14. Sq-31,000
15. Chebi:8361
16. Bristacol
17. Lipemol
18. Prareduct
19. Pravacol
20. Pravasin
21. 3m8608uq61
22. Nsc-759253
23. Sodium;(3r,5r)-7-[(1s,2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
24. Aplactin
25. Lipidal
26. Liprevil
27. Pralidon
28. Pravasine
29. Sanaprav
30. Selipran
31. Vasen
32. Epastatin Sodium
33. Dsstox_cid_27525
34. Dsstox_rid_82395
35. Dsstox_gsid_47525
36. Liplat
37. Vasten
38. Pravastatin, Sodium Salt
39. (3r,5r)-3,5-dihydroxy-7-((1s,2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-(((s)-2-methylbutanoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic Acid, Sodium Salt
40. Cas-81131-70-6
41. Pravastatin Natrium Mayrho Fer
42. Sq 31000
43. 3-beta-hydroxycompactin Sodium Salt
44. Drg-0319
45. Chembl690
46. Unii-3m8608uq61
47. Cres Pravastatin
48. Pravachol (tn)
49. Ncgc00095183-01
50. Pravastatin Sodium [usan:usp:jan]
51. Mfcd00887601
52. Pravastatinsodium,(s)
53. Cs-514 Sodium
54. Pravastatin Sodium- Bio-x
55. Schembl3013
56. Sodium (+)-(betar,deltar,1s,2s,6s,8s,8ar)-1,2,6,7,8,8a-hexahydro-beta,delta,6,8-tetrahydroxy-2-methyl-1-naphthaleneheptanoate, 8-((2s)-2-methylbutyrate)
57. Pravastatin Sodium [mi]
58. Dtxsid6047525
59. Pravastatin Sodium [jan]
60. Hy-b0165a
61. Pravastatin Sodium (jp17/usp)
62. Pravastatin Sodium [usan]
63. Hms2051p05
64. Hms3268l20
65. Hms3413e20
66. Pravastatin Sodium [vandf]
67. Hexahydronaphthalen-1-yl)heptanoate
68. Pravastatin Sodium [mart.]
69. Amy40517
70. Pravastatin Sodium [usp-rs]
71. Pravastatin Sodium [who-dd]
72. Tox21_111474
73. Tox21_300270
74. S3036
75. Akos015896504
76. Akos015964902
77. Ccg-100926
78. Cs-2003
79. Nc00176
80. Nsc 759253
81. Pravastatin Sodium [orange Book]
82. Ncgc00092370-01
83. Ncgc00254232-01
84. Pravastatin Sodium [ep Monograph]
85. 1-naphthaleneheptanoic Acid, 1,2,6,7,8,8a-hexahydro-2-methyl-8-(2-methyl-1-oxobutoxy)-beta,delta,6-trihydroxy-, Monosodium Salt, (1s-(1-alpha(beta-s*,delta-s*),2-alpha,6-alpha,8-beta(r*),8a-alpha))-
86. 1-naphthaleneheptanoic Acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, Monosodium Salt, (1s-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(r*),8aalpha))-
87. Bp164292
88. Pravastatin Sodium [usp Monograph]
89. P1796
90. D00893
91. Pravigard Pac Component Pravastatin Sodium
92. Pravastatin Sodium Component Of Pravigard Pac
93. Q27108059
94. Pravastatin Sodium Salt Hydrate, >=98% (hplc), Powder
95. 2-methyl-8-((s)-2-methylbutanoyloxy)-1,2,6,7,8,8a-
96. Sodium (3r,5r)-3,5-dihydroxy-7-((1s,2s,6s,8s,8ar)-6-hydroxy-
97. (?r,?r,1s,2s,6s,8s,8ar)-1,2,6,7,8,8a-hexahydro-?,?,6-trihydroxy-2-methyl-8-[(2s)-2-methyl-1-oxobutoxy]-1-naphthaleneheptanoic Acid Monosodium Salt
98. (3r,5r)-3,5-dihydroxy-7-((1s,2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-(((s)-2-methylbutanoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoicacid,sodiumsalt
99. 1-naphthaleneheptanoic Acid, 1,2,6,7,8,8a-hexahydro-.beta.,d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, Monosodium Salt, (1s-(1.alpha.(.beta.s*,ds*),2.alpha.,6.alpha.,8.beta.(r*),8a.alpha.))-
100. Sodium (+)-(.beta.r,dr,1s,2s,6s,8s,8ar)-1,2,6,7,8,8a-hexahydro-.beta.,d,6,8-tetrahydroxy-2-methyl-1-naphthaleneheptanoate, 8-((2s)-2-methylbutyrate)
101. Sodium (3r,5r)-3,5-dihydroxy-7-((1s,2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-((s)-2-methylbutanoyloxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoate
102. Sodium (3r,5r)-3,5-dihydroxy-7-[(1s,2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-{[(2s)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoate
Molecular Weight | 446.5 g/mol |
---|---|
Molecular Formula | C23H35NaO7 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 11 |
Exact Mass | 446.22804773 g/mol |
Monoisotopic Mass | 446.22804773 g/mol |
Topological Polar Surface Area | 127 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 662 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Pravachol |
PubMed Health | Pravastatin (By mouth) |
Drug Classes | Antihyperlipidemic |
Drug Label | PRAVACHOL (pravastatin sodium) is one of a class of lipid-lowering compounds, the statins, which reduce cholesterol biosynthesis. These agents are competitive inhibitors of HMG-CoA reductase, the enzyme catalyzing the early rate-limiting step in ch... |
Active Ingredient | Pravastatin sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg; 80mg; 40mg; 20mg |
Market Status | Prescription |
Company | Bristol Myers Squibb |
2 of 4 | |
---|---|
Drug Name | Pravastatin sodium |
Drug Label | Pravastatin sodium tablets are one of a class of lipid-lowering compounds, the HMG-CoA reductase inhibitors, which reduce cholesterol biosynthesis. These agents are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase,... |
Active Ingredient | Pravastatin sodium |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 10mg; 80mg; 40mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Teva; Lupin Pharms; Apotex; Sandoz; Cipla; Watson Labs; Glenmark Generics; Teva Pharms; Pliva Hrvatska Doo; Zydus Pharms Usa; Dr Reddys Labs; Mylan |
3 of 4 | |
---|---|
Drug Name | Pravachol |
PubMed Health | Pravastatin (By mouth) |
Drug Classes | Antihyperlipidemic |
Drug Label | PRAVACHOL (pravastatin sodium) is one of a class of lipid-lowering compounds, the statins, which reduce cholesterol biosynthesis. These agents are competitive inhibitors of HMG-CoA reductase, the enzyme catalyzing the early rate-limiting step in ch... |
Active Ingredient | Pravastatin sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg; 80mg; 40mg; 20mg |
Market Status | Prescription |
Company | Bristol Myers Squibb |
4 of 4 | |
---|---|
Drug Name | Pravastatin sodium |
Drug Label | Pravastatin sodium tablets are one of a class of lipid-lowering compounds, the HMG-CoA reductase inhibitors, which reduce cholesterol biosynthesis. These agents are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase,... |
Active Ingredient | Pravastatin sodium |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 10mg; 80mg; 40mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Teva; Lupin Pharms; Apotex; Sandoz; Cipla; Watson Labs; Glenmark Generics; Teva Pharms; Pliva Hrvatska Doo; Zydus Pharms Usa; Dr Reddys Labs; Mylan |
Anticholesteremic Agents
Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. (See all compounds classified as Hydroxymethylglutaryl-CoA Reductase Inhibitors.)
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14235
Submission : 1999-06-24
Status : Inactive
Type : II
Certificate Number : R1-CEP 2004-168 - Rev 01
Issue Date : 2021-03-04
Type : Chemical and TSE
Substance Number : 2059
Status : Valid
Registration Number : 218MF10474
Registrant's Address : No. 1, Tung-Hsing St. , Shu-Lin, New Taipei City 23850, Taiwan
Initial Date of Registration : 2006-04-27
Latest Date of Registration :
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2012-12-24
Pay. Date : 2012-11-13
DMF Number : 14729
Submission : 2000-02-25
Status : Active
Type : II
Registration Number : 307MF10010
Registrant's Address : 13 Pallagi u(´)t, Debrecen, 4042-Hungary
Initial Date of Registration : 2025-01-09
Latest Date of Registration :
Available Reg Filing : ASMF |
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Registration Number : 218MF10727
Registrant's Address : 13 Pallagi u(´)t, Debrecen, 4042-Hungary
Initial Date of Registration : 2006-09-06
Latest Date of Registration :
Available Reg Filing : ASMF |
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-07-07
Pay. Date : 2014-05-06
DMF Number : 27615
Submission : 2013-10-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15922
Submission : 2002-04-03
Status : Inactive
Type : II
Certificate Number : R1-CEP 2003-025 - Rev 00
Issue Date : 2009-04-14
Type : Chemical
Substance Number : 2059
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16204
Submission : 2002-10-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16975
Submission : 2003-11-20
Status : Inactive
Type : II
Certificate Number : R0-CEP 2005-016 - Rev 02
Issue Date : 2009-11-19
Type : Chemical
Substance Number : 2059
Status : Expired
Registration Number : 219MF10201
Registrant's Address : 1-6-1 Otemachi, Chiyoda-ku, Tokyo
Initial Date of Registration : 2007-06-13
Latest Date of Registration :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16309
Submission : 2002-12-13
Status : Inactive
Type : II
Certificate Number : R1-CEP 2002-009 - Rev 02
Issue Date : 2021-03-17
Type : Chemical
Substance Number : 2059
Status : Valid
NDC Package Code : 58623-0123
Start Marketing Date : 2018-05-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2022-06-07
Registration Number : 20220607-70-B-464-09
Manufacturer Name : Zhejiang Hisun Pharmaceutical Co., Ltd.
Manufacturer Address : No.56, Binhai Road, Jiaojiang District, Taizhou City, Zhejiang Province, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18709
Submission : 2005-08-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18580
Submission : 2005-08-11
Status : Inactive
Type : II
Certificate Number : R1-CEP 2006-167 - Rev 00
Issue Date : 2013-08-21
Type : Chemical
Substance Number : 2059
Status : Withdrawn by Holder
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are Ind...
About the Company : Chongqing Daxin was established in 1941. It is a core member of PKUCare pharmaceutical industry. After nearly 70 year's development, it has become a biotech oriented and comprehens...
About the Company : In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territo...
About the Company : Livzon Group Fuzhou Fuxing Pharmaceutical Co.,Ltd(FFPC),a subsidiary of Livzon Pharmaceutical Group Inc.,was founded in 1989 as a state-owned company.Now Livzon Fuxing has become a...
About the Company : Teva was established in 1901. Our global headquarters are based in Israel. Today we have a portfolio of more than 3,500 medicines, and produce approximately 120 billion tablets and...
About the Company : Tocopharm Co. Limited, built in 2008,is an industry leader in the field of Active Pharmaceutical Ingredients(API), relative pharmaceutical intermediates, derivatives of Quinoline d...
About the Company : Vitalpharms is an excellent pharmaceutical company specializing into import and export, marketing and distributing of API and intermediates of generics all over the world. The int...
About the Company : Zhejiang Hisun Chemical Co., Ltd (hereafter called as ”Hisun Chemical), founded in 1998, is a state-holding enterprise invested by State Development & Investment Corporation(SDIC...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
26
PharmaCompass offers a list of Pravastatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pravastatin manufacturer or Pravastatin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pravastatin manufacturer or Pravastatin supplier.
PharmaCompass also assists you with knowing the Pravastatin API Price utilized in the formulation of products. Pravastatin API Price is not always fixed or binding as the Pravastatin Price is obtained through a variety of data sources. The Pravastatin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pravasine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pravasine, including repackagers and relabelers. The FDA regulates Pravasine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pravasine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pravasine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pravasine supplier is an individual or a company that provides Pravasine active pharmaceutical ingredient (API) or Pravasine finished formulations upon request. The Pravasine suppliers may include Pravasine API manufacturers, exporters, distributors and traders.
click here to find a list of Pravasine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pravasine DMF (Drug Master File) is a document detailing the whole manufacturing process of Pravasine active pharmaceutical ingredient (API) in detail. Different forms of Pravasine DMFs exist exist since differing nations have different regulations, such as Pravasine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pravasine DMF submitted to regulatory agencies in the US is known as a USDMF. Pravasine USDMF includes data on Pravasine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pravasine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pravasine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pravasine Drug Master File in Japan (Pravasine JDMF) empowers Pravasine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pravasine JDMF during the approval evaluation for pharmaceutical products. At the time of Pravasine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pravasine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pravasine Drug Master File in Korea (Pravasine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pravasine. The MFDS reviews the Pravasine KDMF as part of the drug registration process and uses the information provided in the Pravasine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pravasine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pravasine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pravasine suppliers with KDMF on PharmaCompass.
A Pravasine CEP of the European Pharmacopoeia monograph is often referred to as a Pravasine Certificate of Suitability (COS). The purpose of a Pravasine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Pravasine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Pravasine to their clients by showing that a Pravasine CEP has been issued for it. The manufacturer submits a Pravasine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Pravasine CEP holder for the record. Additionally, the data presented in the Pravasine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Pravasine DMF.
A Pravasine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Pravasine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Pravasine suppliers with CEP (COS) on PharmaCompass.
A Pravasine written confirmation (Pravasine WC) is an official document issued by a regulatory agency to a Pravasine manufacturer, verifying that the manufacturing facility of a Pravasine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pravasine APIs or Pravasine finished pharmaceutical products to another nation, regulatory agencies frequently require a Pravasine WC (written confirmation) as part of the regulatory process.
click here to find a list of Pravasine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pravasine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pravasine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pravasine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pravasine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pravasine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pravasine suppliers with NDC on PharmaCompass.
Pravasine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pravasine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pravasine GMP manufacturer or Pravasine GMP API supplier for your needs.
A Pravasine CoA (Certificate of Analysis) is a formal document that attests to Pravasine's compliance with Pravasine specifications and serves as a tool for batch-level quality control.
Pravasine CoA mostly includes findings from lab analyses of a specific batch. For each Pravasine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pravasine may be tested according to a variety of international standards, such as European Pharmacopoeia (Pravasine EP), Pravasine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pravasine USP).